Report cover image

Chronic Obstructive Pulmonary Disease Market -Global Trends and Forecasts(2025 to 2034)

Publisher Factview Research
Published Nov 02, 2025
Length 201 Pages
SKU # FAVR20572977

Description

Chronic Obstructive Pulmonary Disease MarketSize And Forecast

According to Factview Research, the Chronic Obstructive Pulmonary Disease Market was valued at USD 10.58 Billion in 2024 and is projected to reach USD 15.39 Billion by 2034, growing at a CAGR of 4.2% from 2025 to 2034.

Global Chronic Obstructive Pulmonary Disease Market Outlook

The high prevalence of chronic respiratory diseases, new product launches and technological advancements, and rising demand for home care therapeutics devices are some factors that are expected to boom the growth of Global chronic obstructive pulmonary disease market. The increasing number of product approvals from FDA has also helped in market growth. For instance, in April 2025, Circassia Pharmaceuticals plc, announced that they have received FDA approval for Duaklir, that is specially designed for the treatment of COPD. However, the high cost of COPD treatment, increasing problem associated with patent expiry, and the dearth of awareness and knowledge among population about COPD symptoms and indications are some factors that might restrict the market growth.

Global Chronic Obstructive Pulmonary Disease Market Competitive Landscape

The Global Chronic Obstructive Pulmonary Disease Market study report will provide a valuable insight with an emphasis on Global market including some of the major players such as AstraZeneca, Astellas Pharma Inc., Abbott Laboratories, GlaxoSmithKline plc., Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Circassia Pharmaceuticals, Pfizer, Inc., and Almirall.

Table of Contents

201 Pages
1 Introduction Of Global Chronic Obstructive Pulmonary Disease Market
1.1 Overview Of The Market
1.2 Scope Of Report
1.3 Assumptions
2 Executive Summary
3 Research Methodology Of Factview Research
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List Of Data Sources
4 Global Chronic Obstructive Pulmonary Disease Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Chronic Obstructive Pulmonary Disease Market, By Type
5.1 Overview
5.2 Chronic Bronchitis
5.3 Emphysema
6 Global Chronic Obstructive Pulmonary Disease Market, By Treatment-type
6.1 Overview
6.2 Oxygen Therapy
6.3 Lung Transplant
6.4 Drug Therapy
6.4.1 Inhaled Steroids
6.4.2 Combination Inhalers
6.4.3 Oral Steroids
6.4.4 Others
6.5 Surgery
6.6 Others
7 Global Chronic Obstructive Pulmonary Disease Market, By End-user
7.1 Overview
7.2 Hospitals And Clinics
7.3 Homecare Settings
7.4 Others
8 Global Chronic Obstructive Pulmonary Disease Market, By Geography
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest Of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest Of Asia Pacific
8.5 Rest Of The World
8.5.1 Latin America
8.5.2 Middle East
9 Global Chronic Obstructive Pulmonary Disease Market Competitive Landscape
9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
10 Company Profiles
10.1 Astrazeneca
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2 Astellas Pharma Inc.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments
10.3 Abbott Laboratories
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments
10.4 Glaxosmithkline Plc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments
10.5 Novartis Ag
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments
10.6 Boehringer Ingelheim International Gmbh
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments
10.7 Teva Pharmaceutical Industries Ltd
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments
10.8 Circassia Pharmaceuticals
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments
10.9 Pfizer, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments
10.10 Almirall
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments
11 Appendix
11.1 Related Research

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us